الموضوعات
Humans , Hypertension, Malignant/drug therapy , Hypertensive Encephalopathy/pathology , Intensive Care Units/classification , Blood Pressure Monitoring, Ambulatory/methods , Hydralazine/administration & dosage , Labetalol/administration & dosage , Magnetic Resonance Spectroscopy , Nitroglycerin/administration & dosage , Nitroprusside/administration & dosage , Tomographyالموضوعات
Humans , Adult , Female , Pregnancy , Anesthesia, Obstetrical/methods , Pre-Eclampsia/diagnosis , Pre-Eclampsia/therapy , Vision Disorders/diagnosis , Vision Disorders/etiology , Acute Disease , Adjuvants, Anesthesia , Antihypertensive Agents/administration & dosage , Anesthesia, General/methods , Anesthesia, Conduction/methods , Anesthetics, General/administration & dosage , Cesarean Section , Furosemide/administration & dosage , Labetalol/administration & dosageالملخص
OBJECTIVE: The study was designed to evaluate the hemodynamic effects of Esmolol and labetalol in patients undergoing electroconvulsive therapy. MATERIALS AND METHODS: Ninety patients undergoing electroconvulsive therapy treatment were studied according to randomized, double blind placebo controlled protocol. Ninety patients were divided into three groups with thirty patients in each group. Patients received either Esmolol (1 mg/kg), Labetalol (0.25 mg/kg) or Normal Saline (placebo) intravenously just after induction with propofol. The baseline heart rate and blood pressure were recorded. Hemodynamic parameters before and after drug therapy and after the ECT current application, were recorded at different time intervals. RESULTS: It was found that Esmolol significantly attenuated the degree of tachycardia and hypertension after ECT in comparison with placebo in the first three minutes (p<0.05), whereas the rise in HR and blood pressure was significantly blunted in the labetalol group in comparison to placebo, from three minutes onward till ten minutes. (p<0.05). CONCLUSION: It was concluded that Esmolol is effective in blunting the hemodynamic response after ECT stimulus in the first three minutes after application of the electrical current, whereas Labetalol is effective after five minutes onwards till ten minutes.
الموضوعات
Adrenergic beta-Antagonists/administration & dosage , Blood Pressure/drug effects , Depressive Disorder/therapy , Double-Blind Method , Electroconvulsive Therapy , Heart Rate/drug effects , Hemodynamics/drug effects , Humans , Labetalol/administration & dosage , Placebos , Propanolamines/administration & dosage , Treatment Outcomeالموضوعات
Humans , Blood Pressure , Hypertension, Malignant/complications , Hypertension, Malignant/drug therapy , Hypertension, Malignant/therapy , Stroke/complications , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Labetalol/administration & dosage , Labetalol/therapeutic use , Risk Factors , Emergencies/classificationالموضوعات
Humans , Male , Female , Adult , Middle Aged , Anesthesia, General/standards , Hypertension/etiology , Intraoperative Complications/drug therapy , Pheochromocytoma/complications , Postoperative Complications/physiopathology , Atenolol/administration & dosage , Atenolol/therapeutic use , Isoflurane/administration & dosage , Isoflurane/therapeutic use , Labetalol/administration & dosage , Labetalol/therapeutic use , Nitroprusside/administration & dosage , Nitroprusside/therapeutic use , Phentolamine/administration & dosage , Phentolamine/therapeutic use , Pheochromocytoma/diagnosis , Pheochromocytoma/surgery , Prazosin/administration & dosage , Prazosin/therapeutic use , Vecuronium Bromide/administration & dosage , Vecuronium Bromide/therapeutic useالملخص
Caso de tétano severo com síndrome de hiperatividade adrenérgica, tratado na UTI do Departamento de Pediatria do Hospital do Servidor Público Estadual - SP. Os distúrbios cardiovasculares foram controlados pela administraçäo de labetalol, droga anti-hipertensiva com efeito alfa e beta bloqueador
الموضوعات
Humans , Child , Male , Labetalol/therapeutic use , Sympathetic Nervous System/physiopathology , Tetanus/drug therapy , Labetalol/administration & dosage , Tetanus/complicationsالملخص
El dilevalol, isómero óptico del labetalol, tiene efectos vasodilatador y beta-bloqueador, lo que previene la taquicardia refleja; con actividad agonista beta-2 intrínseca. Su escasa actividad alfa-bloqueadora conlleva menos hipotensión ortastática y mejor tolerancia a la primera dosis. Este trabajo evalúa su eficacia y seguridad comparándolo con captopril y nifedipina. Se estudiaron 58 pacientes con hipertensión arterial; después de una fase *placebo* de 2-3 semanas, se incluyeron pacientes con TA diastólica entre 95 y 105 mmHg. En la fase de *tratamiento activo* de 4 semanas, los pacientes fueron asignados aleatoreamente a uno de los 3 fármacos. Inicialmente 15 recibieron dilevalol 200mg/día. Con dilevalol la tensión arterial media (TAM) disminuyó del 118.0+-1.3 a 107.3+-2.7 mmHg en la cuarta semana de tratamiento, con captopril de 117.8+-1.2 a 108.6+-2.7 mmHg. (p<0.05). Cuando se comparó dilevalol con nifedipina, el dilevalol redujo la TAM de 116+-2.0 a 104.3+-3.0 (p<0.05). Ninguno presentó hipotensión ortostática y no hubo efectos secundarios importantes. Estos resultados demuestran que la eficacia y tolerancia de dilevalol es comparable a captopril y nifedipina en pacientes con hipertensión arterial esencial.
الموضوعات
Humans , Middle Aged , Hypertension/therapy , Labetalol/administration & dosage , Labetalol/therapeutic use , Captopril/administration & dosage , Nifedipine/administration & dosageالملخص
Los efectos antihipertensivos agudos de un alfa-beta bloqueador Labetalol, administrado en bolos repetidos de 0.75 mg/Kg, fueron evaluados en 12 pacientes (9 portadores de hipertensión severa y 3 con diagnóstico de emergencia hipertensiva). Las presiones sistólicas y diastólica se redujeron desde X = 221.2 ñ 22.4 a 157.5 ñ 20.9 (29%) y desde X = 136.6 ñ 13.2 a 108.3 ñ 18.6 (20.7%) respectivamente (p <0.001). La frecuencia cardiaca disminuyó gradual y progresivamente y el peak flow no se modificó significativamente. Los efectos colaterales fueron leves y transitorios. Se concluye que el Labetalol endovenoso es una droga efectiva y bien tolerada en el manejo de los pacientes con hipertensión severa y emergencias hipertensivas y se perfila como alternativa frente a los agentes vasodilatadores directos